Noraminophenazoni Fono Vii. Naturland (Metamizole Sodium Monohydrate)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which lowers the production of prostaglandins—key mediators of pain, inflammation, and fever. This reduction in prostaglandin levels diminishes nociceptive signaling and resets the hypothalamic set‑point for body temperature, providing analgesic and antipyretic benefits.

The appropriate dose of Noraminophenazoni Fono Vii. Naturland is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual health factors. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for metamizole sodium in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metamizole sodium belongs to the pyrazolone class, offering strong analgesic and antipyretic effects comparable to certain NSAIDs but with a distinct safety profile, notably a risk of agranulocytosis. Unlike opioids, it does not cause respiratory depression, making it a useful alternative for non‑opioid pain management when appropriate.

Store Noraminophenazoni Fono Vii. Naturland at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme heat to maintain stability and potency.

The product is formulated for rectal administration. It should be inserted according to the prescribing information, typically using a suitable applicator, and the patient should remain in a comfortable position to ensure proper absorption.

The most serious adverse reactions include agranulocytosis, severe skin disorders such as Stevens‑Johnson syndrome, and anaphylactic shock. Patients should be monitored for signs of infection, skin changes, or allergic reactions, and immediate medical attention is required if these occur.

Metamizole sodium should be avoided in individuals with a known hypersensitivity to pyrazolones, a history of agranulocytosis, severe hepatic or renal impairment, and in patients currently receiving other myelosuppressive therapies unless specifically directed by a physician.